Skip to content

PA · EL.PA · MEDICAL - INSTRUMENTS & SUPPLIES

EssilorLuxottica S.A. (EL.PA) intrinsic value and stock valuation

$174.60as of 2026-11-21 · Mkt cap 80.55B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

EssilorLuxottica S.A. DCF and intrinsic value

InvestorsCraft values EL.PA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from EL.PA’s statements →

EssilorLuxottica S.A. Graham Number

Graham Number: $98.81d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Instruments & Supplies Paris 75008 essilorluxottica.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$28.5B+14.6% 5y CAGRd
20112025
Net income
$2.32B+93.7% 5y CAGRd
20112025
Free cash flow
$3.77B+10.3% 5y CAGRd
20112025
Total equity
$39.5B+3.8% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$28.5B$26.5B$25.4B$24.5B$19.8B
Operating income$3.36B$3.45B$3.18B$3.26B$2.57B
Net income$2.32B$2.36B$2.29B$2.15B$1.45B
EPSd$4.98M$5.13M$5.08M$4.83M$3.25M
Operating cash flow$5.29B$4.87B$4.86B$4.78B$4.55B
Capital expenditure-$-1.53B-$-1.52B-$-1.53B-$-1.57B-$-1.03B
Free cash flow$3.77B$3.35B$3.33B$3.21B$3.52B
Total assets$63.9B$64.3B$60.5B$60.6B$59.4B
Total debt$17.1B$13.2B$11.7B$12.2B$13B
Net debt$13.5B$11B$9.1B$10.4B$11.4B
Total equity$39.5B$41B$38.9B$38.1B$35.9B
Cash and short-term investments$3.54B$2.25B$2.56B$1.99B$3.34B
Income statement
20252024202320222021
Revenue$28.5B$26.5B$25.4B$24.5B$19.8B
Cost of revenue$11.2B$9.7B$9.35B$8.9B$7.54B
Gross profit$17.3B$16.8B$16B$15.6B$12.3B
Research and development expenses$664M$630M$593M$600M$579M
Selling, general and administrative expenses$13.2B$12.5B$12.1B$11.7B$9.24B
Other expenses$0.00$197M$228M$60M$66M
Operating expenses$13.9B$13.4B$12.9B$12.3B$9.71B
Cost and expenses$25.1B$23.1B$22.2B$21.2B$17.2B
Interest income$0.00$5M$64M$26M$30M
Interest expense$239M$165M$198M$156M$141M
Depreciation and amortization$3.11B$3.1B$2.95B$2.92B$2.39B
Ebitda$6.47B$6.55B$6.18B$6.1B$4.71B
Operating income$3.36B$3.45B$3.18B$3.26B$2.57B
Total other income/expenses, net-$-166M-$-157M-$-141M-$-232M-$-126M
Income before tax$3.2B$3.29B$3.04B$3.03B$2.18B
Income tax expense$752M$800M$609M$751M$583M
Net income$2.32B$2.36B$2.29B$2.15B$1.45B
Weighted average shares outstanding$459M$453.9M$448.1M$442.1M$438.8M
Weighted average diluted shares outstanding$464.7M$460M$450.8M$445.7M$445.5M
Balance sheet
20252024202320222021
Cash and short-term investments$3.54B$2.25B$2.56B$1.99B$3.34B
Net receivables$3.77B$3.26B$2.97B$2.73B$2.39B
Inventory$3.54B$3.15B$2.75B$2.91B$2.53B
Total current assets$12B$10B$9.72B$8.64B$9.19B
Property, plant and equipment, net$9.05B$9.17B$8.25B$7.76B$7.14B
Goodwill and intangible assets$40.8B$43B$41.3B$73.6B$70.8B
Long-term investments$88M$1.03B$80M$519M$387M
Total non-current assets$51.9B$54.2B$50.8B$51.9B$50.2B
Total assets$63.9B$64.3B$60.5B$60.6B$59.4B
Accounts payable$2.88B$2.66B$2.38B$2.3B$2.22B
Short-term debt$4.93B$3.41B$2.7B$2.01B$1.87B
Deferred revenue$0.00$0.00$209M$222M$179M
Total current liabilities$12.2B$10.6B$9.74B$8.89B$8.93B
Long-term debt$12.1B$9.8B$8.96B$10.2B$11.1B
Deferred revenue, non-current$0.00$21M$15M$27M$27M
Total non-current liabilities$12.3B$12.7B$11.9B$13.5B$14.6B
Capital lease obligations$2.65B$3.65B$3.24B$3.18B$3.07B
Total liabilities$24.4B$23.3B$21.6B$22.4B$23.5B
Common stock$83M$82M$82M$81M$80M
Retained earnings$0.00$2.36B$15.4B$13.4B$12.7B
Accumulated other comprehensive income (loss)$0.00$1.17B$212M$1.23B$139M
Total equity$39.5B$41B$38.9B$38.1B$35.9B
Total investments$88M$1.03B$81M$752M$2.13B
Total debt$17.1B$13.2B$11.7B$12.2B$13B
Net debt$13.5B$11B$9.1B$10.4B$11.4B
Cash flow statement
20252024202320222021
Net income$2.32B$2.49B$2.29B$2.15B$1.45B
Depreciation and amortization$3.11B$3.1B$2.97B$2.92B$2.39B
Stock-based compensation$0.00$162M$220M$191M$160M
Change in working capital-$-468M-$-697M-$-427M-$-356M$329M
Accounts receivable$0.00-$-133M$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00$0.00$0.00
Net cash provided by operating activities$5.29B$4.87B$4.86B$4.78B$4.55B
Investments in property, plant and equipment-$-1.53B-$-1.52B-$-1.53B-$-1.57B-$-1.03B
Acquisitions, net-$-982M-$-1.76B-$-114M-$-1.62B-$-7.13B
Net cash used for investing activities-$-2.64B-$-3.62B-$-1.72B-$-3.29B-$-8.13B
Common stock issued$36M$35M$34M$37M$34M
Common stock repurchased-$-376M-$-274M-$-271M-$-431M-$-317M
Dividends paid-$-547M-$-1.16B-$-487M-$-454M-$-138M
Net cash used for financing activities-$-971M-$-1.65B-$-2.36B-$-2.91B-$-1.97B
Net change in cash$1.29B-$-307M$598M$168M-$-3.1B
Cash at end of period$3.54B$2.25B$2.56B$1.76B$1.59B
Operating cash flow$5.29B$4.87B$4.86B$4.78B$4.55B
Capital expenditure-$-1.53B-$-1.52B-$-1.53B-$-1.57B-$-1.03B
Free cash flow$3.77B$3.35B$3.33B$3.21B$3.52B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About EssilorLuxottica S.A.

        EssilorLuxottica Société anonyme designs, manufactures, and distributes ophthalmic lenses, frames, and sunglasses in North America, Europe, Latin America, Asia, Oceania, and Africa. It operates in five segments: Wholesale, Retail, Lenses and Optical Instruments, Equipment, and Sunglasses and Readers. The Wholesale segment engages in the manufacture and wholesale distribution of luxury and sports eyewear. The Retail segment retails luxury and sports eyewear. The Lenses and Optical Instruments segment offers lenses and small equipment, including Varilux progressive lenses; Crizal antireflective, anti-smudge, and antistatic lenses; Transitions photochromic lenses; Eyezen lenses for users of computers, tablets, smartphones, and other connected devices; Xperio polarized sun lenses; and Nikon and Kodak corrective lens brands. It also provides lens edging and mounting instruments for opticians and prescription laboratories; optometry instruments for eye care professionals, schools, occupational medicine centers, military, and other institutions; and Transitions Signature Gen 8 photochromic lens, as well as develops solutions for online sales of optical products. The Equipment segment offers digital surfacing machines and lens coating machines to prescription laboratories, integrated optical chains, and lens manufacturers. The Sunglasses and Readers segment provides non-prescription sunglasses and reading glasses under the Foster Grant, Gargoyles, Magnivision, Corinne McCormack, Monkey Monkey, Ryders Eyewear, and SolarShield brands; Reebok, Steve Madden, Betsey Johnson, Nine West, Dockers, French Connection, Ironman, Rawlings, Bodyglove, Panama Jack, Marvel, and Disney; Bolon, Molsion, Qina, and Prosun brands; and Mujosh and Aojo brands. It has a network of 490 prescription laboratories and edging-mounting facilities. The company was formerly known as Essilor International Société Anonyme and changed its name to EssilorLuxottica Société anonyme in October 2018. EssilorLuxottica Société anonyme was founded in 1849 and is headquartered in Paris, France.

        CEO
        Francesco Milleri
        Employees
        153.5K
        Beta
        0.54

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of EssilorLuxottica S.A. (EL.PA)?

        InvestorsCraft does not currently publish an intrinsic value for EL.PA. How the IC value is calculated.

        Is EL.PA undervalued?

        InvestorsCraft does not publish an undervaluation signal for EL.PA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.